Stockreport

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

BeiGene, Ltd. - American Depositary Shares  (BGNE) 
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm Check Earnings Report
PDF Vote recommends a class-wide PD-L1 expression level cut-off across PD-1 inhibitors in advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction c [Read more]